Basit öğe kaydını göster

dc.contributor.authorAkalin, Halis
dc.contributor.authorCagatay, Atahan
dc.contributor.authorKORTEN, VOLKAN
dc.contributor.authorYildirmak, Taner
dc.contributor.authorWillke, Ayse
dc.contributor.authorSAYAN, MURAT
dc.contributor.authorSargin, Fatma
dc.contributor.authorİNAN, DİLARA
dc.contributor.authorSevgi, Dilek Y.
dc.contributor.authorCelikbas, Aysel K.
dc.contributor.authorYasar, Kadriye
dc.contributor.authorKaptan, Figen
dc.contributor.authorSAYIN KUTLU, SELDA
dc.contributor.authorFisgin, Nuriye T.
dc.contributor.authorInci, Ayse
dc.contributor.authorCeran, Nurgul
dc.contributor.authorKaraoglan, Ilkay
dc.contributor.authorÇELEN, MUSTAFA KEMAL
dc.contributor.authorKoruk, Suda T.
dc.contributor.authorCeylan, Bahadir
dc.date.accessioned2021-03-03T12:48:49Z
dc.date.available2021-03-03T12:48:49Z
dc.date.issued2016
dc.identifier.citationSAYAN M., Sargin F., İNAN D., Sevgi D. Y. , Celikbas A. K. , Yasar K., Kaptan F., SAYIN KUTLU S., Fisgin N. T. , Inci A., et al., "HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey", AIDS RESEARCH AND HUMAN RETROVIRUSES, cilt.32, sa.1, ss.26-31, 2016
dc.identifier.issn0889-2229
dc.identifier.othervv_1032021
dc.identifier.otherav_304044e6-7cdd-4902-828b-885c7bc469de
dc.identifier.urihttp://hdl.handle.net/20.500.12627/36922
dc.identifier.urihttps://doi.org/10.1089/aid.2015.0110
dc.description.abstractHIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts.
dc.language.isoeng
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectViroloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectVİROLOJİ
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectTemel Tıp Bilimleri
dc.titleHIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey
dc.typeMakale
dc.relation.journalAIDS RESEARCH AND HUMAN RETROVIRUSES
dc.contributor.departmentKocaeli Üniversitesi , Kocaeli Sağlık Hizmetleri Meslek Yüksekokulu , Tıbbi Laboratuar Teknikleri Programı
dc.identifier.volume32
dc.identifier.issue1
dc.identifier.startpage26
dc.identifier.endpage31
dc.contributor.firstauthorID229537


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster